Sirtratumab vedotin (anti-SLITRK6) 是一种抗体药物偶联物 (ADC),由 SLTRK6(SLIT 和 NTRK 样家族成员 6,“SLIT 和 NTRK 样家族,成员 6”)和细胞毒性物质单甲基奥瑞他汀 E (MMAE)组成。它向表达 SLITRK6 的肿瘤细胞递送一种小分子微管破坏剂单甲基 auristatin E (MMAE)。 Sirtratumab vedotin (anti-SLITRK6) 具有用于膀胱癌、转移性尿路上皮癌研究的潜力。
Sirtratumab vedotin (anti-SLITRK6), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. Sirtratumab vedotin (anti-SLITRK6) has the potential for Bladder Cancer, Metastatic urothelial cancer research.